Zheng Mei, Wen Xiaomin, Wang Feng. Efficacy of Procaterol Combined with Montelukast in the Treatment of Bronchial Asthma in Children. [J]. 27(3):23-26(2021)
DOI:
Zheng Mei, Wen Xiaomin, Wang Feng. Efficacy of Procaterol Combined with Montelukast in the Treatment of Bronchial Asthma in Children. [J]. 27(3):23-26(2021) DOI: 10.13407/j.cnki.jpp.1672.108X.2021.03.007.
Efficacy of Procaterol Combined with Montelukast in the Treatment of Bronchial Asthma in Children
Objective: To probe into the efficacy of procaterol combined with montelukast in the treatment of bronchial asthma in children and its effects on chemokine-like factor-1 (CKLF-1)
eosinophil cationic protein (ECP)
interleukin-12 (IL-12)
interleukin-13 (IL-13) and lung function. Methods: Totally 94 children with bronchial asthma admitted into our hospital from Aug. 2017 to Apr. 2019 were extracted to be divided into the control group and the observation group via the random number table
with 47 cases in each group. Both groups received conventional treatment such as anti-inflammatory
asthma relieving and bronchiectasia treatment. The control group was given montelukast sodium tablets
while the observation group received procaterol on the basis of the control group. The clinical efficacy of two groups were compared. The levels of CKLF-1
ECP
IL-12
IL-13 and changes of lung function in two groups were analyzed before and after treatment. Results: The total effective rate of the observation group was higher than that of the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the observation group (8.51%) and the control group (4.26%
P>0.05). Before treatment
there was no significant difference in the levels of CKLF-1
ECP
IL-12
IL-13 and lung function indexes between two groups (P>0.05). After treatment
the levels of IL-12
forced expiratory volume in 1 second (FEV1)
FEV1/FVC
peak expiratory flow (PEF) and peak expiratory flow rate (PEFR) in the observation group were higher than those in the control group
while the levels of CKLF-1
ECP and IL-13 were lower than those in the control group (P<0.05). Conclusion: Procatechol combined with montelukast in the treatment of children with bronchial asthma can improve the lung function
regulate the expression levels of CKLF-1
ECP
IL-12 and IL-13
and improve the clinical efficacy without increasing adverse drug reactions.
关键词
丙卡特罗孟鲁司特支气管哮喘趋化素样因子-1嗜酸粒细胞阳离子蛋白
Keywords
procaterolmontelukastbronchial asthmachemokine-like factor-1eosinophils cationic protein
Effects of Montelukast Combined with Vitamin D Preparations on Pulmonary Function, Oxidation-antioxidant Imbalance and Quality of Life in Children with Bronchial Asthma
Efficacy of Cetirizine Hydrochloride Drops Combined with Fluticasone Propionate Inhalation in theTreatment of Allergic Rhinitis Complicated with Bronchial Asthma in Children
Effects of Probioticson Inflammatory Factors and Oxidative Stress Markers in Children with Allergic Asthma
Current Status and Clinical Evaluation of Asthma Medication in Children: Based on Survey Results of 46 Medical Institutions
Salbutamol and Ipratropium Bromide Combined with Magnesium Sulfate in the Treatment of Children with Acute Attack of Bronchial Asthma
Related Author
Zhang Chengwei
Lin Jin
Wang Hongmei
Dong Liangliang
Huang Mengmeng
Wu Hongmei
Kong Xia
Li Yinfang
Related Institution
Maternal and Child Health Care Hospital of Lishui
Liaocheng Second People’s Hospital, Shandong Liaocheng
Nanjing Hospital Affiliated to Nanjing Medical University, the First Hospital of Nanjing
National Children’s Medical Center, Beijing Children’s Hospital, Capital Medical University